Advanced search×

Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report.

J Clin Psychiatry 71(8):1040-6 (2010) PMID 20673551

To address issues concerning potential treatment-emergent "suicidality," a consensus conference was convened March 23-24, 2009.

DOI: 10.4088/JCP.10cs06070ablu
Version: za2963e q8zae q8zb4 q8zcb q8zdc q8ze2 q8zfd q8zg1

Similar articles you may find interesting…

  1. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine.

    Neuropsychopharmacology 33(13):3201-12 (2008) PMID 18418363

    We estimated the relative SERT and NET occupancy of paroxetine and venlafaxine in human subjects to assess the relative magnitude of SERT and NET inhibition. Outpatient subjects (N=86) meeting criteria for major depression were enrolled in a multicenter, 8 week, randomized, double-blind, parallel gr...
  2. Community responses to a suicidal crisis: implications for suicide prevention.

    Suicide Life Threat Behav 41(1):79-86 (2011) PMID 21309826

    We conducted a cross-sectional, random-digit-dial survey to evaluate public responses to a hypothetical question: "If someone you knew was suicidal, what would you do first?" Younger people were more likely to call a suicide hotline, and less likely to go to an emergency room (ER) or call 911; immig...
  3. Insomnia and Sleep Duration as Mediators of the Relationship Between Depression and Hypertension Incidence.

    Am J Hypertens 23(1):62-9 (2010) PMID 19893498

    BackgroundDepression has been found to predict the incidence of hypertension and other adverse cardiovascular events in prospective studies. Insomnia and short sleep duration, which are typical symptoms of depression, have also been shown to increase the risk for hypertension inciden...